Amedeo Smart

Free Medical Literature Service

 

Amedeo

Antiretroviral Therapy
  Free Subscription

Articles published in
Antivir Ther
    June 2025
  1. THUY TD, Ha NT, Cuong DD, Long LV, et al
    Cost-effectiveness of tenofovir alafenamide fumarate for treatment of chronic hepatitis B: Evidence from a tertiary hospital in Vietnam.
    Antivir Ther. 2025;30:13596535251349054.
    >> Share

  2. VAN HEMELRYCK S, Van Landuyt E, Deleu S, Leopold L, et al
    Pediatric darunavir/cobicistat fixed-dose combination tablet for dispersion: Bioequivalence versus separate agents in healthy participants and acceptability in children living with human immunodeficiency virus-1.
    Antivir Ther. 2025;30:13596535251349336.
    >> Share

    April 2025
  3. LABATE L, Rossetti B, Russo C, Cassol C, et al
    Durability of multi-drug antiretroviral therapy (mega-ART) in treatment-experienced people with HIV in the ARCA database.
    Antivir Ther. 2025;30:13596535251317054.
    >> Share

    February 2025
  4. SUDEEP N, Kojima N, Klausner JD
    Nirmatrelvir treatment duration and frequency of COVID-19 rebound.
    Antivir Ther. 2025;30:13596535251323728.
    >> Share

  5. PICKERING RT, Asundi A, Olson A, Soden K, et al
    Increased insulin resistance following switch from efavirenz to cobicistat-boosted elvitegravir.
    Antivir Ther. 2025;30:13596535251314571.
    >> Share

    December 2024
  6. METWALY AM, Elkaeed EB, Alsfouk AA, Ibrahim IM, et al
    Repurposing FDA-approved drugs for COVID-19: targeting the main protease through multi-phase in silico approach.
    Antivir Ther. 2024;29:13596535241305536.
    >> Share

  7. PASSEROTTO RA, Lamanna F, Salvo PF, Iannone V, et al
    Effectiveness of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) as switch strategy in virologically-suppressed patients: real world data from a monocentric cohort.
    Antivir Ther. 2024;29:13596535241306467.
    >> Share

    October 2024
  8. ZHANG Q, Xu J, Liu D, Wang L, et al
    Comparative efficacy and safety of tenofovir amibufenamide vs tenofovir alafenamide in the initial 48-week treatment of high viral load chronic hepatitis B: A single-centre retrospective study.
    Antivir Ther. 2024;29:13596535241284226.
    >> Share

    April 2024
  9. VAN HEMELRYCK S, Van Landuyt E, Hufkens V, Vanveggel S, et al
    Assessment of swallowability and acceptability of scored darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) fixed-dose combination (FDC) tablets in HIV-1-infected children aged >/=6 to <12 years, using matching placebo tablets: A ran
    Antivir Ther. 2024;29:13596535241248282.
    >> Share

    February 2024
  10. LEPIK KJ, Hunt OL, Bacani N, Wang L, et al
    Adverse drug reactions attributed to generic substitution of antiretroviral medications among HIV treatment and pre-exposure prophylaxis clients in British Columbia, Canada.
    Antivir Ther. 2024;29:13596535241233128.
    >> Share

    December 2023
  11. MARGOT N, Pennetzdorfer N, Naik V, Rhee M, et al
    Cross-resistance to entry inhibitors and lenacapavir resistance through Week 52 in study CAPELLA.
    Antivir Ther. 2023;28:13596535231220754.
    >> Share

    June 2023
  12. ARMSTRONG I, Lacombe-Duncan A, Shokoohi M, Persad Y, et al
    Feminizing hormone therapy in a Canadian cohort of transgender women with and without HIV.
    Antivir Ther. 2023;28:13596535231182505.
    >> Share

  13. ZILWA N, Mpejane O, Mehboob G, Gill S, et al
    Fanconi syndrome, diabetes insipidus, and acute kidney injury due to tenofovir disoproxil fumarate: A case report.
    Antivir Ther. 2023;28:13596535231186727.
    >> Share

    February 2023
  14. PETERS E, Iwuji AC
    Efficacy, safety and tolerability of Biktarvy in HIV-1 infection: A scoping review.
    Antivir Ther. 2023;28:13596535231159030.
    >> Share

  15. ROLLE CP, Castano J, Nguyen V, Patel K, et al
    Treatment-related early discontinuations and adverse events among newly diagnosed people living with HIV initiating integrase inhibitors in a real-world setting.
    Antivir Ther. 2023;28:13596535231163703.
    >> Share

  16. DE WAAL R, Rabie H, Technau KG, Eley B, et al
    Abacavir safety and effectiveness in young infants with HIV in South African observational cohorts.
    Antivir Ther. 2023;28:13596535231168480.
    >> Share

    October 2022
  17. TYAGI A, Tong Y, Rabideau DJ, Reynolds Z, et al
    Antiretroviral therapy adherence patterns, virological suppression, and emergence of drug resistance: A nested case-control study from Uganda and South Africa.
    Antivir Ther. 2022;27:13596535221114822.
    >> Share

    August 2022
  18. ALVAREZ E, Campbell L, Tinago W, Garcia-Leon A, et al
    The renal-bone axis in older people living with HIV on stable antiretroviral therapy: A sub-analysis of the GS-US-104-0423 study.
    Antivir Ther. 2022;27:13596535221094898.
    >> Share

  19. VAN DER VEER MA, Jacobs TG, Bukkems LH, Colbers AP, et al
    Pharmacokinetic interaction between raltegravir and rifampicin in an infant with HIV exposed to active TB: a case report.
    Antivir Ther. 2022;27:13596535221119932.
    >> Share

    June 2022
  20. MUSENGIMANA G, Tuyishime E, Kiromera A, Malamba SS, et al
    Acquired HIV drug resistance among adults living with HIV receiving first-line antiretroviral therapy in Rwanda: A cross-sectional nationally representative survey.
    Antivir Ther. 2022;27:13596535221102690.
    >> Share

  21. EUROPEAN PREGNANCY AND PAEDIAT, Lyons A, Thompson L, Chappell E, et al
    Outcomes of etravirine-based antiretroviral treatment in treatment-experienced children and adolescents living with HIV in Europe and Thailand.
    Antivir Ther. 2022;27:13596535221092182.
    >> Share

    April 2022
  22. ROEDIGER R, Smyth EK, Dieterich D
    Adefovir for lamivudine-resistant hepatitis B.
    Antivir Ther. 2022;27:13596535211067605.
    >> Share

  23. LEE WA, Cheng AK
    Tenofovir alafenamide fumarate.
    Antivir Ther. 2022;27:13596535211067600.
    >> Share

  24. ABDOOL KARIM SS, Baxter C, Abdool Karim Q
    Advancing HIV prevention using tenofovir-based pre-exposure prophylaxis.
    Antivir Ther. 2022;27:13596535211067589.
    >> Share

  25. PAN CQ
    The role of tenofovir disoproxil fumarate for preventing vertical transmission of hepatitis B.
    Antivir Ther. 2022;27:13596535221076640.
    >> Share

  26. CHOUDHARY MC, Mellors JW
    The transformation of HIV therapy: One pill once a day.
    Antivir Ther. 2022;27:13596535211062396.
    >> Share

  27. SCHINAZI RF, Patel D, Ehteshami M
    The best backbone for HIV prevention, treatment, and elimination: Emtricitabine+tenofovir.
    Antivir Ther. 2022;27:13596535211067599.
    >> Share

  28. YANG T, Oliyai R, Kent KM
    The making of the one pill-Developing single tablet regimens for HIV and for HCV.
    Antivir Ther. 2022;27:13596535211067606.
    >> Share

    November 2021
  29. PRESSIAT C, Dainguy E, Treluyer JM, Yonaba C, et al
    Comparison of three galenic forms of lamivudine in young West African children living with Human Immunodeficiency Virus.
    Antivir Ther. 2021;26.
    >> Share

    May 2021
  30. MAGGIOLO F, Gianotti N, Comi L, Di Filippo E, et al
    Rilpivirine plus cobicistat-boosted darunavir as alternative to standard three-drug therapy in HIV-infected, virologically suppressed subjects: Final results of the PROBE 2 trial.
    Antivir Ther. 2021;26.
    >> Share

  31. SCHEIBE K, Urbanska A, Jakubowski P, Hlebowicz M, et al
    Low prevalence of doravirine-associated resistance mutations among polish human immunodeficiency-1 (HIV-1)-infected patients.
    Antivir Ther. 2021;26.
    >> Share

    January 2021
  32. LEE JE, Lee SO, Heo J, Kim DW, et al
    Comparative outcomes of lopinavir/ritonavir and hydroxychloroquine for the treatment of COVID-19 with mild-to-moderate severity: A retrospective observational study.
    Antivir Ther. 2021;26.
    >> Share

  33. UGARTE A, De la Mora L, Martinez-Rebollar M, Mallolas J, et al
    An unexpected adverse effect: Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide-induced cholestasis.
    Antivir Ther. 2021;26.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016